Sexual Dysfunction, Physiological
Conditions
Keywords
Dapoxetine hydrochloride (PRILIGY), Premature ejaculation
Brief summary
This study will use electronic health services databases to describe the usage patterns of dapoxetine hydrochloride (PRILIGY) in Germany and Italy with a focus on describing the extent and proportion of patients with characteristics suggestive of the use of PRILIGY within, versus outside of the intended use population.
Detailed description
This study will use anonymized (nameless) patient data from electronic health services databases in Germany and Italy to describe the proportion of PRILIGY (dapoxetine hydrochloride) usage among those patients with characteristics suggestive of the use of PRILIGY within versus outside (eg, those with contraindications) of the intended use (IU) population. This is an observational study; no investigational drug will be administered.
Interventions
DRUGPRILIGY (dapoxetine hydrochloride)
The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
Sponsors
Cegedim Strategic Data
Janssen Research & Development, LLC
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* Received a prescription for PRILIGY * Treated by physicians who contributed data to the IMS Disease Analyzer database for Germany and Thales database for Italy
Exclusion criteria
* Age not specified * Sex not specified as male * Fewer than 6 months (183 days) of history in the electronic health services databases before receiving the first prescription for PRILIGY (At least 6 months of history in the database is not required for the patients of the German urologists).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion patients receiving PRILIGY prescriptions who are within (versus outside of) the IU population. | For up to 1 year |
Secondary
| Measure | Time frame |
|---|---|
| The number of patients prescribed PRILIGY who do not have a diagnosis suggestive of the approved indication. | For up to 1 year |
| The number of patients prescribed PRILIGY who have conditions or use medications that are described in the special warnings and precautions section of the PRILIGY Summary of Product Characteristics (SPC) | For up to 1 year |
| The number of patients prescribed PRILIGY who are at risk for bleeding due to current use of nonsteroidal anti-inflammatory drugs (NSAID's) and warfarin. | For up to 1 year |
Outcome results
None listed